Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

AIDS

Volumn 16, Issue 17, 2002, Pages 2295-2301

  Huisman, Maarten T ^a   Smit, Johan W ^c   Crommentuyn, Kristel M L ^b   Zelcer, Noam ^a   Wiltshire, Hugh R ^d   Beijnen, Jos H ^b   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c Cobra Therapeutics Ltd ^*  (United Kingdom)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Combination therapy; Multidrug resistance; Multidrug resistance protein 2 (MRP2); Oral medicine; Pharmacokinetics drug interactions; Protease inhibitors

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN 1; ELACRIDAR; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 5; PROBENECID; PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SULFINPYRAZONE; UNCLASSIFIED DRUG; VALSPODAR; VERLUKAST;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DOG; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; DOGS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; EPITHELIAL CELLS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RITONAVIR; SAQUINAVIR; TRANSDUCTION, GENETIC;

EID: 0037159933     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211220-00009     Document Type: Article

References (35)

1. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
2. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998, 286:1439-1445.
3. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999, 16:1206-1212.
4. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000, 28:655-660.
5. Huisman MT, Smit JW, Schinkel AH. Significance of P-glyco-protein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000, 14:237-242.
6. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
7. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999, 104:1441-1447.
8. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001, 59:806-813.
9. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999, 1461:359-376.
10. Wijnholds J, Scheffer GL, van der Valk MA, van der Valk P, Beijnen JH, Scheper RJ, et al. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 1998, 188:797-808.
11. Wijnholds J, de Lange EC, Scheffer GL, van den Berg DJ, Mol CAAM, van der Valk MA, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000, 105:279-285.
12. König J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999, 1461:377-394.
13. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 2000, 58:1357-1367.
14. St Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1495-R1503.
15. Dietrich CG, de Waart DR, Ottenhoff R, Schoots IG, Oude Elferink RP. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2 -deficient rats. Mol Pharmacol 2001, 59:974-980.
16. Dietrich CG, de Waart DR, Ottenhoff R, Bootsma AH, van Gennip AH, Elferink RP. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis 2001, 22:805-811.
17. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-15670.
18. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61 :3458-3464.
19. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000, 92:1651-1656.
20. Srinivas RV, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998, 42:3157-3162.
21. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001, 15:675-681.
22. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, et al. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? AIDS 2001, 15:1353-1358.
23. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999, 56:383-389.
24. Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ, Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett 1997, 419:112-116.
25. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LJM, et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998, 101:1310-1319.
26. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999, 96:6914-6919.
27. Wijnholds J, Mol CAAM, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000, 97:7476-7481.
28. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92:1295-1302.
29. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC833. Cancer Res 1991, 51:4226-4233.
30. den Ouden D, van den Heuvel M, Schoester M, van Rens G, Sonneveld P. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia 1996, 10:1930-1936.
31. Louvard D. Apical membrane aminopeptidase appears at site of cell-cell contact in cultured kidney epithelial cells. Proc Natl Acad Sc USA 1980, 77:4132-4136.
32. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 2000, 83:375-383.
33. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 2000, 83:366-374.
34. van der Sandt I, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 2001, 15:483-491.
35. Evers R, Zaman GJR, van Deemter L, Jansen H, Calafat J, Oomen LCJM, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996, 97:1211-1218.